| | |
Anti-CTLA-4
|
Anti-PD-1
|
Combination
|
Fisher’s test
|
|---|
| |
(n = 37)
|
(n = 27)
|
(n = 11)
|
p value
|
|---|
| |
No. (%)
|
No. (%)
|
No. (%)
|
|---|
|
Gender
|
Female
|
12 (32)
|
11 (41)
|
4 (36)
|
0.848
|
| |
Male
|
25 (68)
|
16 (59)
|
7 (64)
| |
|
Age at treatment initiation
|
Mean (SD)
|
66.2 (13)
|
69.9 (14)
|
59.9 (13)
|
1
|
| |
Median
|
67.4
|
71
|
61.1
| |
|
ECOG PS (pretreatment)
|
0
|
28 (76)
|
19 (70)
|
7 (64)
|
0.736
|
| |
> 1
|
9 (24)
|
8 (30)
|
4 (36)
| |
|
LDH (pretreatment)
|
Normal
|
31 (91)
|
19 (70)
|
9 (82)
|
0.114
|
| |
Elevated
|
0 (9)
|
8 (30)
|
2 (18)
| |
| |
Unknown
|
3
|
0
|
0
| |
|
Response to treatment
|
POD
|
22 (59)
|
10 (37)
|
4 (36)
|
0.01
|
| |
SD
|
10 (27)
|
5 (19)
|
1 (9)
| |
| |
PR
|
5 (14)
|
8 (30)
|
2 (18)
| |
| |
CR
|
0
|
2 (7)
|
4 (36)
| |
| |
UNC
|
0
|
2 (7)
|
0
| |
|
Toxicity
|
None
|
8 (22)
|
4 (15)
|
0
| |
| |
Mild
|
20 (54)
|
15 (55)
|
4 (36)
|
0.16
|
| |
Severe
|
9 (24)
|
8 (30)
|
7 (64)
| |
|
GI toxicity
|
Mild
|
9 (23.1)
|
12 (42.9)
|
3 (27.3)
|
0.08
|
| |
Severe
|
6 (15.4)
|
3 (10.7)
|
6 (54.5)
| |
|
Skin toxicity
|
Mild
|
15 (38.5)
|
17 (60.7)
|
5 (45.5)
|
0.43
|
| |
Severe
|
0
|
1 (3.6)
|
1 (9.1)
| |
|
Endocrine toxicity
|
Mild
|
5 (12.8)
|
11 (39.2)
|
4 (36.4)
|
0.71
|
| |
Severe
|
0
|
1 (3.6)
|
1 (9.1)
| |
|
Required treatment termination
|
Yes
|
4 (11)
|
3 (11)
|
6 (54)
|
0.006
|
| |
No
|
33 (89)
|
24 (89)
|
5 (46)
| |
- Summary of clinical features from 75 melanoma patients treated with anti-CTLA-4 (n = 37), anti-PD-1 (n = 27), or anti-CTLA-4 and anti-PD-1 (n = 11). LDH lactate dehydrogenase, POD progression of disease, SD stable disease, PR partial response, CR complete response, UNC unclassified. Fisher’s exact test was used to examine the significance of the association between patient characteristics and treatment type. Two anti-CTLA-4 patients were sampled twice (11-311, in 2011 and 2013; 12-071, in 2012 and 2013), and one anti-PD-1 patient was sampled twice (13-185, in 2015 and 2016)
